Back to top

Analyst Blog

GlaxoSmithKline plc (GSK - Analyst Report) performed disappointingly in the second quarter of 2012, missing the Zacks Consensus Estimate both in terms of revenues and earnings. Results were negatively impacted by a number of factors including European austerity measures and weaker performance in the US due to generic competition and discontinuation of certain products.

Following the disappointing results, management at Glaxo lowered their revenue guidance for 2012. The company now expects revenues to remain flat year-over-year (at constant exchange rate) mainly due to EU pricing pressure. Earlier, Glaxo was expecting revenues to grow from 2011 levels.

We believe the current price reflects the negative news and are reverting to a Neutral recommendation from Underperform. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

In addition to facing generic competition, most of Glaxo’s products face significant competition from small as well as large pharmaceutical companies. Glaxo’s Consumer Healthcare segment faces competition from big companies like Colgate-Palmolive (CL - Analyst Report), Johnson & Johnson (JNJ - Analyst Report), Procter & Gamble (PG - Analyst Report), Pfizer (PFE - Analyst Report) and Novartis (NVS - Analyst Report).

Although Glaxo continues to face challenges in the form of EU pricing pressure, US health care reform, generic competition and currency fluctuations, we are pleased with the company’s efforts to combat the situation by inking deals/making acquisitions. Glaxo has also made significant progress with its late-stage pipeline.

We think the company possesses one of the stronger late-stage pipelines in large-cap pharma. Late-stage candidates include Breo (chronic obstructive pulmonary disease: regulatory review), albiglutide (regulatory submission planned in early 2013), dabrafenib (oncology: regulatory review), trametinib (oncology: regulatory review) and sirukumab (rheumatoid arthritis, phase III initiated in August 2012). The successful development and commercialization of these candidates should boost the company’s top line.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CTPARTNERS… CTP 13.33 +3.49%
SAIA INC SAIA 45.65 +1.00%
VASCO DATA… VDSI 13.57 +0.67%
AMEDISYS IN… AMED 20.18 +0.10%
FIRSTSERVIC… FSRV 55.66 -0.13%